ARMP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ARMP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.
Armata Pharmaceuticals's adjusted revenue per share for the three months ended in Dec. 2023 was $0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Dec. 2023.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.
During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Armata Pharmaceuticals was 42.60% per year. The lowest was -12.80% per year. And the median was 10.15% per year.
As of today (2024-04-27), Armata Pharmaceuticals's current stock price is $2.76. Armata Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $0.00. Armata Pharmaceuticals's Cyclically Adjusted PS Ratio of today is .
During the past 13 years, the highest Cyclically Adjusted PS Ratio of Armata Pharmaceuticals was 0.86. The lowest was 0.01. And the median was 0.22.
The historical data trend for Armata Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Armata Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cyclically Adjusted Revenue per Share | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Armata Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Armata Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Armata Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.
What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?
Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.
We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, Armata Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Dec. 2023 (Change) | * | Current CPI (Dec. 2023) |
= | 0 | / | 129.4194 | * | 129.4194 | |
= | 0.000 |
Current CPI (Dec. 2023) = 129.4194.
Armata Pharmaceuticals Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201403 | 4.000 | 99.695 | 5.193 |
201406 | 2.196 | 100.560 | 2.826 |
201409 | 2.289 | 100.428 | 2.950 |
201412 | 3.367 | 99.070 | 4.398 |
201503 | 3.400 | 99.621 | 4.417 |
201506 | 1.889 | 100.684 | 2.428 |
201509 | 3.405 | 100.392 | 4.390 |
201512 | 3.048 | 99.792 | 3.953 |
201603 | 2.524 | 100.470 | 3.251 |
201606 | 1.635 | 101.688 | 2.081 |
201609 | 0.367 | 101.861 | 0.466 |
201612 | 0.227 | 101.863 | 0.288 |
201703 | 0.242 | 102.862 | 0.304 |
201706 | 0.071 | 103.349 | 0.089 |
201709 | 0.060 | 104.136 | 0.075 |
201712 | 0.029 | 104.011 | 0.036 |
201803 | 0.000 | 105.290 | 0.000 |
201806 | 0.000 | 106.317 | 0.000 |
201809 | 0.000 | 106.507 | 0.000 |
201812 | 0.000 | 105.998 | 0.000 |
201903 | 0.000 | 107.251 | 0.000 |
201906 | 0.000 | 108.070 | 0.000 |
201909 | 0.000 | 108.329 | 0.000 |
201912 | 0.000 | 108.420 | 0.000 |
202003 | 0.000 | 108.902 | 0.000 |
202006 | 0.000 | 108.767 | 0.000 |
202009 | 0.000 | 109.815 | 0.000 |
202012 | 0.000 | 109.897 | 0.000 |
202103 | 0.000 | 111.754 | 0.000 |
202106 | 0.000 | 114.631 | 0.000 |
202109 | 0.000 | 115.734 | 0.000 |
202112 | 0.000 | 117.630 | 0.000 |
202203 | 0.000 | 121.301 | 0.000 |
202206 | 0.000 | 125.017 | 0.000 |
202209 | 0.000 | 125.227 | 0.000 |
202212 | 0.000 | 125.222 | 0.000 |
202303 | 0.000 | 127.348 | 0.000 |
202306 | 0.000 | 128.729 | 0.000 |
202309 | 0.000 | 129.860 | 0.000 |
202312 | 0.000 | 129.419 | 0.000 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.
For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
During the past 13 years, the highest Cyclically Adjusted PS Ratio of Armata Pharmaceuticals was 0.86. The lowest was 0.01. And the median was 0.22.
Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.
Thank you for viewing the detailed overview of Armata Pharmaceuticals's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Richard Rychlik | officer: Corporate Controller and PFO | 5005 MCCONNELL AVENUE, LOS ANGELES CA 90066 |
Deborah Birx | director, officer: Chief Executive Officer | 3300 LOWELL STREET NW, WASHINGTON DC 20008 |
Julianne Averill | officer: Chief Financial Officer | 361 NEWBURY STREET, SUITE 500, BOSTON MA 02115 |
Erin Butler | officer: Vice President,Finance & Admin | 4375 LOMA RIVIERA COURT, SAN DIEGO CA 92110 |
Theravance Inc | director, 10 percent owner | 1350 OLD BAYSHORE HIGHWAY, SUITE 400, BURLINGAME CA 94010 |
Jules Haimovitz | director | 601 108TH AVENUE NE, SUITE 1200, BELLEVUE WA 98004 |
Innoviva Strategic Opportunities Llc | director, 10 percent owner | 1209 ORANGE STREET, WILMINGTON DE 19801 |
Robin Kramer | director | 999 VANDERBILT BEACH ROAD, 3RD FLOOR, NAPLES FL 34109 |
Steven Robert Martin | officer: Chief Financial Officer | 11011 NORTH TORREY PINES ROAD, LA JOLLA CA 92037 |
Kostas D Odysseas | director | 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830 |
Sarah J. Schlesinger | director | C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
Jeremy Curnock Cook | director | TARGETED GENETICS CORP, 1100 OLIVE WAY STE 100, SEATTLE WA 98101 |
Michael S Perry | director | C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155 |
Todd C. Peterson | director | C/O ARMATA PHARMACEUTICALS, INC., 4503 GLENCOE AVENUE, MARINA DEL REY CA 90292 |
H Stewart Parker | director |
From GuruFocus
By PRNewswire PRNewswire • 05-11-2023
By PRNewswire PRNewswire • 06-01-2022
By PRNewswire PRNewswire • 03-17-2023
By PRNewswire PRNewswire • 07-01-2022
By PRNewswire PRNewswire • 08-01-2022
By PRNewswire PRNewswire • 06-02-2022
By PRNewswire PRNewswire • 07-11-2022
By PRNewswire • 09-26-2023
By PRNewswire • 11-14-2023
By PRNewswire PRNewswire • 05-23-2022